Pharmaceutical Technology on MSN
EC approves Roche’s Gazyva to treat active lupus nephritis
The decision is based on outcomes from the Phase II NOBILITY and Phase III REGENCY trials.
In a new study, researchers examined the Renal Activity Index for Lupus (RAIL) diagnostic tool to assess its success for ...
Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard ...
But for others, the disease is more severe – with constant symptoms Although researchers know that lupus is caused by the immune system mistakenly attacking the body’s own tissues and organs, it isn’t ...
In the latest episode of Australian producer Bruna Papandrea’s new podcast, Australian actress Asher Keddie reflects on her successes, her career, and the shared Lupus journeys that connect both host ...
Dermatologists long reluctant to tackle cutaneous lupus erythematosus may be more open to treating patients with approvals ...
The younger that someone is when certain illnesses hit, especially before puberty, the more severe symptoms may be. And while ...
There's a new frontier in treating autoimmune diseases.
A new study examined whether routine blood test measures could help in identifying disease flares in people with systemic ...
Lupus diagnoses are rising, especially among young women. Experts explain why cases are increasing, why symptoms are often ...
Although researchers know that lupus is caused by the immune system mistakenly attacking the body’s own tissues and organs, it isn’t entirely clear what triggers this response. But a new study ...
News-Medical.Net on MSN
Single-cell RNA sequencing uncovers diverse CD4⁺ T-cell subtypes in pediatric lupus
Detailed mapping of CD4⁺ T cells from children with systemic lupus erythematosus (SLE) has revealed distinct immune cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results